Mayne Pharma (ASX:MYX): Share Price Movement, Women’s Health Expansion and Business Strategy Explained

Aditi Sarkar

20 August 2026 08:25 PM AEST

Mayne Pharma (ASX:MYX): Share Price Movement, Women’s Health Expansion and Business Strategy Explained

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Mayne Pharma (ASX:MYX) closed at AUD 3.35, up 3.72% on 20 August 2026.
The company develops and commercialises specialty pharmaceutical products across Women’s Health, Dermatology and other therapeutic areas.
FY26 results highlighted Revenue of AUD 383.7 million, gross Margin of 65% and underlying EBITDA of AUD 31.7 million.
Investors continue to monitor Women’s Health growth, DistributeRx expansion, Manufacturing capacity and product partnerships.

Mayne Pharma Group (ASX:MYX) shares closed at AUD 3.35, up 3.72% on 20 August 2026. The movement reflects a positive Trading session as investors continue to assess the company’s specialty pharmaceutical portfolio, Women’s Health growth strategy and operational transition.

Daily share price movements can reflect changes in investor sentiment, trading activity, valuation expectations and broader market conditions. However, a single-session movement does not necessarily indicate a change in the company’s underlying fundamentals, financial position or long-term operating outlook.

Mayne Pharma develops, manufactures and commercialises pharmaceutical products across Women’s Health, Dermatology and other therapeutic areas. The company operates through branded pharmaceutical products, specialty medicines, direct-to-patient distribution and manufacturing capabilities.

The broader Australian market closed higher on the day. The S&P/ASX 200 (ASX:XJO) closed at 9,083.80 points, up 0.33% today, while the S&P/ASX 300 (ASX:XKO) closed at 9,019.90 points, up 0.37% today. Within the healthcare sector, the S&P/ASX 200 Health Care (ASX:XHJ) closed at 32,044.30 points, up 1.39% today.

Specialty pharmaceutical platform

Mayne Pharma operates as a specialty pharmaceutical company focused on developing and commercialising differentiated medicines. Its portfolio includes Women’s Health products, Dermatology treatments and other prescription medicines across international markets.

The company’s Business model combines product development, commercialisation, licensing opportunities and manufacturing capabilities. Investors generally assess pharmaceutical companies through product sales growth, prescription trends, market access, gross margins, regulatory progress and pipeline development.

Women’s Health has become an important growth area for Mayne Pharma, with products including BIJUVA and NEXTSTELLIS gaining attention through increased prescription activity. The company has also expanded its distribution capabilities through Adelaide Apothecary, supporting direct-to-patient pharmaceutical distribution.

The pharmaceutical sector remains influenced by competition, healthcare access, reimbursement conditions, intellectual property protection and the ability to successfully commercialise products.

FY26 performance and business update

Mayne Pharma’s FY26 results highlighted revenue of AUD 383.7 million, down 6% compared with FY25. Gross margin increased to 65%, up 411 basis points compared with the prior corresponding period, while direct contribution was AUD 107.3 million, down 2%. Underlying EBITDA was AUD 31.7 million, down 33% compared with FY25.

The company reported stronger performance in Women’s Health, with fourth-quarter FY26 total prescriptions for BIJUVA increasing 21% compared with the prior corresponding period. NEXTSTELLIS Demand cycles increased 16% compared with the prior corresponding period, supported by increased commercial activity.

Mayne Pharma received AUD 14.4 million from Cosette during FY26 through court-ordered recovery of legal costs and interest. The company also completed an AUD 18 million upgrade of its Salisbury manufacturing facility, supporting increased production capability.

The company executed a Lease for a new automated Adelaide Apothecary facility, which is expected to increase prescription processing capacity approximately seven-fold to more than 2.5 million prescriptions per annum. The expanded Facility is intended to support DistributeRx growth from early 2027.

Mayne Pharma reported cash and marketable securities of AUD 80.0 million as at 30 June 2026. The company also highlighted continued Investment in Women’s Health sales and promotional capability to support product growth.

Investors continue to monitor whether the company’s Women’s Health momentum, manufacturing investments and distribution initiatives can support future Earnings growth.

Factors investors generally monitor

Mayne Pharma’s performance is influenced by prescription trends, product launches, regulatory conditions, market access and pharmaceutical competition.

Women’s Health growth remains a key focus area. Investors monitor prescription volumes, market share, reimbursement access and the ability of products such as BIJUVA and NEXTSTELLIS to expand within target markets.

Dermatology performance is another important consideration. The company has faced competitive pressures in some products, making pricing discipline, product mix and channel execution important factors.

Manufacturing capability is also closely monitored. Facility upgrades can support additional production capacity, but investors assess execution timelines, utilisation rates and commercial returns.

Licensing and Partnership opportunities remain relevant because pharmaceutical companies often use external collaborations to expand market reach and create additional revenue streams.

Cash management is another focus area. Investors assess whether operating cash generation can support investment in sales, marketing, manufacturing and product development.

Understanding the share price movement

Mayne Pharma’s 3.72% share price increase on 20 August 2026 may reflect changes in investor sentiment, trading activity or positioning within the healthcare sector. However, daily share price movements alone do not necessarily represent changes in the company’s underlying fundamentals.

Pharmaceutical stocks can experience short-term Volatility as investors reassess product performance, market access, earnings expectations and strategic initiatives.

For Mayne Pharma, investors are likely to continue monitoring Women’s Health growth, DistributeRx expansion, manufacturing capacity and the company’s ability to improve earnings performance.

Conclusion

Mayne Pharma (ASX:MYX) closed at AUD 3.35, up 3.72% on 20 August 2026. The company continues to develop its specialty pharmaceutical platform across Women’s Health, Dermatology and international markets.

While the daily share price movement reflects market activity, investors generally assess Mayne Pharma through broader factors including prescription growth, gross margins, product portfolio performance, manufacturing expansion and commercial execution. FY26 updates highlighted continued Women’s Health momentum, improved margin performance and investment into future distribution capabilities.

FAQs

Q: What was Mayne Pharma’s share price movement on 20 August 2026?

A: Mayne Pharma (ASX:MYX) closed at AUD 3.35, up 3.72% on 20 August 2026.

Q: What does Mayne Pharma do?

A: Mayne Pharma develops and commercialises specialty pharmaceutical products across Women’s Health, Dermatology and other therapeutic areas.

Q: What were Mayne Pharma’s FY26 results?

A: Mayne Pharma reported FY26 revenue of AUD 383.7 million, gross margin of 65%, direct contribution of AUD 107.3 million and underlying EBITDA of AUD 31.7 million.

Q: What products are supporting Mayne Pharma’s growth strategy?

A: Investors are monitoring products including BIJUVA and NEXTSTELLIS within Women’s Health, alongside broader specialty pharmaceutical initiatives.

Q: What factors influence Mayne Pharma’s performance?

A: Investors generally monitor prescription growth, regulatory conditions, product launches, manufacturing capability, partnerships and cash management.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.